Adagene Inc. has reached a significant milestone in its clinical development efforts by announcing that the first patient has been dosed in a Phase 1 study of its innovative cancer therapy, ADG138. This double-masked HER2×CD3 bispecific T-cell engager is designed to target HER2-positive advanced solid tumors. The successful dosing represents a critical step in the company's efforts to bring new treatment options to patients suffering from these challenging cancers.
Peter Luo, Ph.D., Chairman and CEO of Adagene, emphasized the importance of this milestone, stating, "Dosing the first patient with ADG138 is an important step in moving our double-masked T-cell engager from preclinical research into the clinic." He highlighted the promising preclinical data that supports the therapy's potential in treating patients who have not responded to existing treatments.
BACKGROUND
Adagene Inc., incorporated in the People's Republic of China, operates under the SIC code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on the Nasdaq under the ticker symbol ADAG. Adagene is a clinical-stage biotechnology firm focused on the discovery and development of novel antibody-based therapies, leveraging advanced technologies to address unmet medical needs.
WHAT THE FILING SAYS
According to the recent SEC filing (accession number 0001104659-26-129932), the Phase 1 study aims to evaluate the safety and preliminary efficacy of ADG138 in patients with HER2-positive advanced solid tumors. The study will start with a dose of 2 mg of ADG138, with subsequent doses determined based on emerging clinical data.
IMPACT
This development may significantly impact patients with HER2-positive cancers, providing new hope for those who have exhausted other treatment options. The advancement of ADG138 could also influence the broader pharmaceutical preparations industry, as competitors may need to reassess their product pipelines and strategies in light of Adagene's progress.
WHAT'S NEXT
The filing does not specify what happens next in the clinical trial process, but the company will likely continue monitoring patient responses and safety as the trial progresses.
Read Next
Cloudflare's Michelle Zatlyn Sells Over $1.5M in Shares
Zurn Elkay VP LaMotte Jeremy L Reports Stock Sale
XTI Aerospace CEO Jeremy Schneiderman Reports Stock Exchange
Jennifer Salinas acquires 366,529 shares in Cerence Inc.
Mentz Christian acquires 125,979 shares of Cerence Inc.
Cerence CEO Acquires 819,039 Shares in Stock Transaction










